Skip to content
Search

Latest Stories

PSA annual review: GPhC meets 15 out of 18 standards

The General Pharmaceutical Council (GPhC) has met 15 out of 18 Standards of Good Regulation in 2020-21, according to the annual performance review conducted by the Professional Standards Authority for Health and Social Care (PSA)

The PSA reviewed the council’s performance during March 1, 2020 to February 28, 2021, and found that the GPhC responded and adapted well to the Covid-19 pandemic.


The report noted that it frequently published information for pharmacists and pharmacy technicians as well as for members of the public.

The GPhC met all the standards of general standards, guidance and standards, education and training and registration.

However, it could not meet three out of five standards within the Fitness to Practice category.

The PSA report acknowledged that the council had taken efforts to address the previous concerns raised in the 2019-20 performance review, and that improvements had been made.

It also recognised that the pandemic delayed the action plan put in place by the GPhC and had adversely affected how quickly concerns were progressed.

Commenting on the review, GPhC chief executive Duncan Rudkin said: “It is a key priority for us to make improvements in our fitness to practise processes, first and foremost to meet the concerns of the public and patients, to ensure fairness to registrants, and to meet the Standards of the PSA.

“As the 2020/21 performance report highlights, some of the improvement work we had planned during this performance review period started later than anticipated because we needed to respond quickly and effectively to the challenges and pressures of the pandemic.

The Council received high numbers of concerns during the pandemic, but could not progress investigations quickly and had to switch to remote hearings, Rudkin said.

He added that the council took forward work to finalise and implement its strategy on changing the way to manage concerns about pharmacy professionals.

Rudkin said that implementing this change remains a priority area for the GPhC to be able to take swift action and protect patients, along with promoting a learning culture that would allow pharmacy professionals “to deal with any concerns and go back to practising in appropriate circumstances.”

“We are pleased that the performance report recognises the progress made in the particular circumstances of the pandemic. The report also recognises that while we had to re-prioritise and adapt our plans, we have managed to complete almost all of the planned improvement actions.

“As highlighted in the report, it will take time to see evidence of the impact of some of these changes.

“We expect the PSA will see further improvements when they review our performance for 2021/22.”

More For You

Walgreens Boots Alliance acquired by Sycamore in deal

Walgreens Boots Alliancehas entered into “a definitive agreement” to be acquired by Sycamore Partners

Gettyimages

Walgreens Boots Alliance acquired by Sycamore in £18.3 billion deal

Walgreens Boots Alliance(WBA) has entered into “a definitive agreement” to be acquired by Sycamore Partners, a private equity firm specializing in retail, consumer and distribution-related investments.

“The total value of the transaction represents up to $23.7 billion (£18.3 billion),” the company announced late last night (6).

Keep ReadingShow less
Professor Sir Stephen Powis at a press briefing

Professor Sir Stephen Powis, was appointed national medical director of NHS England in 2018

NHS

NHS England’s top doctor to step down following Amanda Pritchard’s resignation

Just a week after NHS England chief executive Amanda Pritchard announced her resignation, the organisation’s national medical director, Professor Sir Stephen Powis, has confirmed he will step down this summer after more than seven years in the role.

In a statement released on Thursday, Professor Powis revealed that he had informed Pritchard of his intention to leave in a letter back in January.

Keep ReadingShow less
PDA calls on GP practices to use funding boost to improve job security for pharmacists

Now, it is time to focus on the community pharmacy contract

gettyimages

PDA urges GP practices to ensure funding boost supports employed pharmacists

The Pharmacists' Defence Association (PDA) has called on GP practicesto ensure that all healthcare professionals they employ, including pharmacists, benefit from the 7.2% funding boost they received under a newly agreed contract.

GP employers are encouraged to improve “job security, pay and conditions” for employees with this increased funding.

Keep ReadingShow less
Fourth Shift: Investment in Innovative Medicines Crucial for NHS 10-Year Plan Success

Medicines should be viewed as an investment rather than a cost

gettyimages

ABPI wants to see a ‘fourth shift’ in NHS 10-Year Health Plan


The Association of the British Pharmaceutical Industry (ABPI) has called on the government to increase investment in innovative medicines and vaccines, describing it as a crucial “fourth shift” necessary to ensure the NHS is fit for the future.

Keep ReadingShow less
Lawrence Tallon named new MHRA chief executive

Lawrence Tallon

Photo credit: Sciana Network

Lawrence Tallon named new MHRA chief executive

Lawrence Tallon has been appointed as the new chief executive officer of the Medicines and Healthcare products Regulatory Agency (MHRA), effective 1 April 2025.

He will succeed Dame June Raine DBE, who is retiring after leading the agency since 2019.

Keep ReadingShow less